No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CTLT240719C55000
- 2.90
- -0.10-3.33%
15min DelayClose Jul 12 16:00 ET
2.90High2.90Low
2.90Open3.00Pre Close2 Volume4.19K Open Interest55.00Strike Price580.00Turnover42.71%IV0.56%PremiumJul 19, 2024Expiry Date2.58Intrinsic Value100Multiplier5DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type0.8140Delta0.0863Gamma19.52Leverage Ratio-0.0786Theta0.0070Rho15.89Eff Leverage0.0195Vega
Intraday
- 5D
- Daily
News
Catalent Price Target Maintained With a $63.50/Share by RBC Capital
Catalent Price Target Maintained With a $63.50/Share by RBC
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.
RBC Capital Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63.5
RBC Capital analyst Sean Dodge maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $63.5.According to TipRanks data, the analyst has a success rate of 39.3% and a
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.
Unusual Options Activity: CTLT, STX and Others Attract Market Bets, CTLT V/OI Ratio Reaches 250.0
EST Jul 1st Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.O
Comments
I've been on the hunt for a low-risk, yet relatively high-yield investment strategy, and I'm sure many of you feel the same. 🤔While I'm hesitant to dive into stocks like $NVIDIA(NVDA.US$ , fearing the price might be peaking and a sudden drop is imminent, I also find the stable dividends of companies like $Coca-Cola(KO.US$ underwhelming for my limited capital. 💡 But recently, I stumbled upon the concept of diversified investing, wh...
23
The pharma giant $Eli Lilly and Co(LLY.US$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
71
$Catalent(CTLT.US$ why drop
$Catalent(CTLT.US$ 👀63$ all set target
RECAP
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
23
Read more